PROJECT

Projects

Environmental & Social Review Summary

Project Number

46445

Company Name

UNIAO QUIMICA FARMACEUTICA NACIONAL SA

Date ESRS Disclosed

Aug 26, 2022

Country

Brazil

Region

Latin America and the Caribbean

Last Updated Date

Jun 9, 2023

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Nov 2, 2022
Signed : Feb 2, 2023
Invested : Jun 5, 2023

Sector

other

Industry

other

Department

Regional Industry MAS LAC & EUR

Project Description

UniãoQuímicaFarmacêutica Nacional S.A. (“UQ” or the “Company”) is among the 10th largest national pharmaceutical companies in Brazil, with more than 85 years of history. Headquartered in Sao Paulo, the Company has eight manufacturing facilities in Brazil and more than 7650 employees. UQ is focused on human health (65% of sales, mostly to the private sector), animal health (19% of sales) and 16% of sales are related to contract manufacturing, selling to top international brands.

The company's industrial capacity is composed of eight plants, including the following facilities:

(i) Brasília (DF) and Pouso Alegre (MG) plants have their production directed to the Human Health Division,

(ii) Embu Guaçu (SP) unit is dedicated to medicinal products for the Animal Health Division, and,

(iii) the Anovis unit in Taboão da Serra (SP) and Inovat, at Guarulhos (SP), are dedicated to the outsourcing of drugs production for the pharmaceutical industry in the solid and liquid forms. The Bthek plant is intended for biotechnology. Also, the company has a graphic plant that produces cartridges, package inserts, adhesive labels, as well as working with promotional materials for the pharmaceutical industry. This facility includes a logistic center for distribution of products.   

The proposed investment consists of an 8-year secured A Loan of BRL 340 million (US$65 million) in UQ. From this, BRL 100 million will be used to upgrade two of their existing plants to be able to produce vaccines (both for COVID-19 and other uses as well). BRL 235 million will be used to increase manufacturing capacity for certain products such as antibiotics, corticoids, and anti-inflammatory, anaesthetics, among others, serving the hospital segment. The remaining portion of the IFC loan will be used to finance working capital needs.

Due to COVID-19, there was a spike in demand from hospitals and UQ needs to increase the capacity in 2 of their existing plants to properly serve its clients. A big portion of these investments would be related to COVID-19 related drugs. There will not be any new construction outside the plants (no new footprint), all investments would be within the existing plants.                         

Overview of IFC's Scope of Review

IFC’s environmental and social (“E&S”) appraisal included meetings in Sao Paulo Brazil with UQ representatives responsible for Chief Executive Officer, Chief Financial Officer, Production and Engineering Manager, Environmental and Safety Manager, Safety Coordinators, Quality Manager, Supply Chain Manager, Security Manager and Human Resources (HR) Manager and Environmental, Health and Safety (EHS) officers at the corporate level from June 1st, 2nd, and 13th, 2022.

IFC also visited UQ facilities in Sao Paulo (Plants Genom and Inovat) and in Brasilia (Plants Unidade Fabril Brasilia and Bthek) in June 2022 and conducted interviews with workers in these facilities. 

IFC reviewed procedures and plans related to E&S management at the corporate and facility level allied to organizational capacity in support of UQ’s E&S practices. The due diligence included a review of supporting information for all sites such as environmental management systems manual and procedures, HR policies, occupational health, and safety (OHS) programs and statistics, workplace, and environmental monitoring data (e.g., air emissions and effluents), life and fire safety in pharmacies, waste management programs, emergency preparedness procedures, energy saving and GHG reduction programs, and the strategy for social programs. IFC performed an assessment of labor and working conditions, including interviews and focus groups conversations with salesforces and union representatives. Compliance with applicable E&S national law was also reviewed including relevant permits and licenses related to construction and operational activities. 

The appraisal included review of media reports and other relevant information necessary to understand the contextual risks associated with the Project.                                                   

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan